Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points $75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points
Covered in this story
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.